Scandion Oncology A/S
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SCOL.ST research report →
Companywww.scandiononcology.com
Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of chemotherapy resistance. Its lead product candidate includes the SCO-101, an oral compound that is in clinical Phase Ib and Phase II studies in cancer patients. The company's other product candidate is SCO-201, which is in preclinical trial for the treatment of solid tumors.
- CEO
- Francois Regis Martelet
- IPO
- 2018
- Employees
- 4
- HQ
- Copenhagen, DK
Price Chart
Valuation
- Market Cap
- $962.52K
- P/E
- -0.01
- P/S
- 0.00
- P/B
- 0.08
- EV/EBITDA
- 0.19
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -285.39%
- ROIC
- -678.24%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-56,207,163 · -43.37%
- EPS
- $-0.24 · 75.00%
- Op Income
- $-63,091,612
- FCF YoY
- 45.69%
Performance & Tape
- 52W High
- $0.18
- 52W Low
- $0.00
- 50D MA
- $0.01
- 200D MA
- $0.05
- Beta
- 1.86
- Avg Volume
- 8.75M
Get TickerSpark's AI analysis on SCOL.ST
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our SCOL.ST Coverage
We haven't published any research on SCOL.ST yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate SCOL.ST Report →